Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Bright Minds Biosciences Inc. is one of them.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotechnology company developing highly selective 5-HT2 agonists to treat drug-resistant epilepsy, depression, and other CNS disorders. Its pipeline focuses on breakthrough serotonergic compounds designed to address unmet medical needs in neurological and neuropsychiatric conditions.

Bright Minds Biosciences Inc. (NASDAQ:DRUG)  is actively advancing its clinical programs, including the Phase 2 BREAKTHROUGH study of BMB-101, a selective 5-HT2C agonist targeting adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE). The trial evaluates safety, tolerability, and efficacy, reflecting the business’s focus on drug-resistant epilepsy and other challenging CNS conditions, placing it among the best psychedelic stocks for investors seeking neuropsychiatric innovation.

The corporation is also enhancing its scientific leadership, expanding its Scientific Advisory Board with five epilepsy research experts to support clinical and development strategies. The company will present at four major healthcare conferences between August and September 2025, including the International Epilepsy Congress in Lisbon and the Cantor Global Healthcare Conference, with the latter webcast live for investors.

Market interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) is growing, with recent stock gains driven by clinical progress and increased trading volume. Analysts maintain a Strong Buy rating, with a 12-month price target averaging $85, highlighting confidence in the company’s pipeline and therapeutic potential.

While we acknowledge the potential of DRUG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.